VAVladimir Atanasov

Vladimir Atanasov

*This is an algorithmically generated author record based on publicly available information.

Vladimir Atanasov has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pfizer Versus Moderna COVID-19 Vaccine Effectiveness Against Mortality: Evidence from Linked Mortality and Vaccination Records in Indiana

    by Sadia Farzana, Francesco Maria Rossi, Qian Eric Luo, Jeff Whittle, Kevin McGurk, Benjamin W. Weston, Andy Ye Yuan, Ali Moghtaderi, Vladimir Atanasov, Bernard S. Black

    Objective: It is commonly believed in the public health community that the mRNA vaccines from Pfizer and Moderna were broadly similar in preventing COVID-19 mortality, with perhaps a small advantage for Moderna. We revisit this question, using a research design that controls for healthy-vaccinee bias. Methods: We studied deaths among persons aged 15 years or greater from January 2021 through December 2022 in Indiana, linked to vaccination records, using an outcome measure, namely COVID-19 Excess Mortality Percentage (CEMP), which uses non-COVID natural mortality to control for HVB. Results: We find both large healthy-vaccinee bias for both vaccines, and larger bias for Pfizervaccinees: Pfizer recipients were healthier and thus would have faced lower COVID-19 mortality without vaccination. For ages 60+, we find almost 50% higher COVID-19 remaining mortality risk (RMR) for Pfizer vaccinees receiving primary vaccination over a “core period” from 2Q2021 through 1Q2022: the average Pfizer/Moderna RMR ratio was 1.49. For ages 15–59, this ratio was 1.25, but was not statistically significant. For booster dose for ages 60+, the average Pfizer/Moderna RMR ratio was 1.34. For 2Q2022 through 4Q2022, after the major Omicron wave, we find much lower vaccine effectiveness and no significant Pfizer–Moderna difference. Conclusions: During the period with both good vaccine availability and high COVID-19 mortality (2Q-2021–1Q2022), the Moderna vaccine was associated with lower COVID-19 mortality, relative to the Pfizer vaccine. A possible explanation is the higher Moderna dose (100 μg vs. 30 for Pfizer). After that period, a high percentage of the population had natural immunity from prior COVID-19 infection; we find only small mortality gains from vaccination, with no significant Pfizer–Moderna difference. Policy Implications: Controlling for healthy-vaccinee bias, Moderna was associated with lower COVID-19 mortality, relative to Pfizer. This difference was not known in real-time due to the failure of the available studies to address healthy-vaccinee bias. Controlling for such bias is vital when making vaccination policy.

  • Open Access

    COVID-19 Vaccine Effectiveness Against Mortality in the Omicron Period: Evidence from Linked Mortality and Vaccination Records

    by Sadia Farzana, Francesco Maria Rossi, Katie S. Allen, Qian Luo, Jeff Whittle, Kevin McGurk, Benjamin W. Weston, Andy Ye Yuan, Ali Moghtaderi, Vladimir Atanasov, et al.

    Objective: This study aimed to assess COVID-19 vaccine effectiveness against death (VE), controlling for healthy vaccinee bias. Methods: We link all adult deaths through year-end 2022 in the State of Indiana, U.S.A., to vaccination records and identify which deceased received primary vaccination (measured as either one or two initial doses) and which received one or two booster doses. We measure COVID-19 mortality with the COVID Excess Mortality Percentage (CEMP). CEMP is calculated, for a group defined by various characteristics (age, sex, time period), as COVID-19 deaths divided by non-COVID natural deaths. The CEMP outcome measure accounts for healthy vaccinee bias by using non-COVID natural mortality to control for differences in population health. Results: We find a large healthy vaccinee bias. Controlling for this bias, we find substantial VE for primary vaccination and the first booster dose during the first five vaccine-available calendar quarters, from 1Q2021 through 1Q2022 (end of Omicron infection wave). However, over 2Q–4Q2022, we find no evidence for primary-vaccination VE, and find moderate but statistically insignificant booster VE, which largely wanes by 4Q2022. Conclusions: It is known that by 2Q2022, most people had natural immunity from prior COVID-19 infection. Thus, our results for 2Q–4Q2022 largely reflect comparing hybrid (infection plus vaccination) immunity to infection-only immunity. In this period, we find negligible mortality benefit from primary vaccination, and moderate but waning benefit from a booster dose. Policy Implications: Controlling for healthy vaccinee bias is crucial when estimating VE. We found limited VE against COVID-19 mortality over 2Q–4Q2022, but lacked data for more recent periods.


  • Open Access

    Circulatory diseases and the wide sex and ethnic life expectancy gaps in Bulgaria since 2010

    by A. Angelov, A. Atanassov, V. Atanasov, S. Gyoshev, J. Saraivanova, V. Volodina


  • Understanding racial/ethnic disparities in COVID-19 mortality using a novel metric: COVID excess mortality percentage

    by Andy Ye Yuan, Vladimir Atanasov, Natalia Barreto, Lorenzo Franchi, Jeff Whittle, Benjamin Weston, John Meurer, Qian (Eric) Luo, Bernard Black

    Prior research on racial/ethnic disparities in COVID-19 mortality has often not considered to what extent they reflect COVID-19–specific factors, versus preexisting health differences. This study examines how racial/ethnic disparities in COVID-19 mortality vary with age, sex, and time period over April-December 2020 in the United States, using mortality from other natural causes as a proxy for underlying health. We study a novel measure, the COVID excess mortality percentage (CEMP), defined as the COVID-19 mortality rate divided by the non-COVID natural mortality rate, converted to a percentage, where the CEMP denominator controls (albeit imperfectly) for differences in population health. Disparities measured using CEMP deviate substantially from those in prior research. In particular, we find very high disparities (up to 12:1) in CEMP rates for Hispanics versus Whites, particularly for nonelderly men. Asians also have elevated CEMP rates versus Whites, which were obscured in prior work by lower overall Asian mortality. Native Americans and Blacks have significant disparities compared with White populations, but CEMP ratios to Whites are lower than ratios reported in other work. This is because the higher COVID-19 mortality for Blacks and Native Americans comes partly from higher general mortality risk and partly from COVID-specific risk.


  • Open Access

    Selection Effects and COVID-19 Mortality Risk after Pfizer vs. Moderna Vaccination: Evidence from Linked Mortality and Vaccination Records

    by Vladimir Atanasov, Natalia Barreto, Jeff Whittle, John Meurer, Benjamin W. Weston, Qian (Eric) Luo, Andy Ye Yuan, Lorenzo Franchi, Ruohao Zhang, Bernard Black

    Prior research generally finds that the Pfizer-BioNTech (BNT162b2) and Moderna (mRNA1273) COVID-19 vaccines provide similar protection against mortality, sometimes with a Moderna advantage due to slower waning. However, most comparisons do not address selection effects for those who are vaccinated and with which vaccine. We report evidence on large selection effects, and use a novel method to control for these effects. Instead of directly studying COVID-19 mortality, we study the COVID-19 excess mortality percentage (CEMP), defined as the COVID-19 deaths divided by non-COVID-19 natural deaths for the same population, converted to a percentage. The CEMP measure uses non-COVID-19 natural deaths to proxy for population health and control for selection effects. We report the relative mortality risk (RMR) for each vaccine relative to the unvaccinated population and to the other vaccine, using linked mortality and vaccination records for all adults in Milwaukee County, Wisconsin, from 1 April 2021 through 30 June 2022. For two-dose vaccinees aged 60+, RMRs for Pfizer vaccinees were consistently over twice those for Moderna, and averaged 248% of Moderna (95% CI = 175%,353%). In the Omicron period, Pfizer RMR was 57% versus 23% for Moderna. Both vaccines demonstrated waning of two-dose effectiveness over time, especially for ages 60+. For booster recipients, the Pfizer–Moderna gap is much smaller and statistically insignificant. A possible explanation for the Moderna advantage for older persons is the higher Moderna dose of 100 μg, versus 30 μg for Pfizer. Younger persons (aged 18–59) were well-protected against death by two doses of either vaccine, and highly protected by three doses (no deaths among over 100,000 vaccinees). These results support the importance of a booster dose for ages 60+, especially for Pfizer recipients. They suggest, but do not prove, that a larger vaccine dose may be appropriate for older persons than for younger persons.


  • Open Access

    Understanding COVID-19 Vaccine Effectiveness against Death Using a Novel Measure: COVID Excess Mortality Percentage

    by Vladimir Atanasov, Natalia Barreto, Jeff Whittle, John Meurer, Benjamin W. Weston, Qian (Eric) Luo, Lorenzo Franchi, Andy Ye Yuan, Ruohao Zhang, Bernard Black

    COVID-19 vaccines have saved millions of lives; however, understanding the long-term effectiveness of these vaccines is imperative to developing recommendations for booster doses and other precautions. Comparisons of mortality rates between more and less vaccinated groups may be misleading due to selection bias, as these groups may differ in underlying health status. We studied all adult deaths during the period of 1 April 2021–30 June 2022 in Milwaukee County, Wisconsin, linked to vaccination records, and we used mortality from other natural causes to proxy for underlying health. We report relative COVID-19 mortality risk (RMR) for those vaccinated with two and three doses versus the unvaccinated, using a novel outcome measure that controls for selection effects. This measure, COVID Excess Mortality Percentage (CEMP), uses the non-COVID natural mortality rate (Non-COVID-NMR) as a measure of population risk of COVID mortality without vaccination. We validate this measure during the pre-vaccine period (Pearson correlation coefficient = 0.97) and demonstrate that selection effects are large, with non-COVID-NMRs for two-dose vaccinees often less than half those for the unvaccinated, and non-COVID NMRs often still lower for three-dose (booster) recipients. Progressive waning of two-dose effectiveness is observed, with an RMR of 10.6% for two-dose vaccinees aged 60+ versus the unvaccinated during April–June 2021, rising steadily to 36.2% during the Omicron period (January–June, 2022). A booster dose reduced RMR to 9.5% and 10.8% for ages 60+ during the two periods when boosters were available (October–December, 2021; January–June, 2022). Boosters thus provide important additional protection against mortality.


  • Mismarking in Mutual Funds

    by Vladimir Atanasov, John J. Merrick, Philipp Schuster

    We study mismarking of newly purchased odd lot and two classes of round lot structured product positions in mutual funds. Such mismarking artificially inflates net asset values and overstates cumulative returns. Applied to funds launched after January 2010, a simulation-tested mismarking fund filter identifies 12 Highly Questionable funds managing $75 billion. The performance of these funds matches closely the predicted pattern of mismarking: extremely high alpha and skewness, particularly immediately after launch. We show that structured product mismarking can seriously inflate return-since-inception metrics. We also provide evidence consistent with return smoothing for one quarter of the sample structured product funds. The inflated performance metrics benefit fund managers through significantly higher Sharpe ratios, Morningstar ratings, and asset growth but cause material losses to later investor cohorts. This paper was accepted by Agostino Capponi, finance. Funding: P. Schuster gratefully acknowledges funding by the Deutsche Forschungsgemeinschaft [Grant SCHU 3049/1-1]. Supplemental Material: Data and the online appendices are available at https://doi.org/10.1287/mnsc.2022.4366 .


  • Open Access

    Understanding COVID-19 Vaccine Effectiveness Against Death Using a Novel Measure: COVID Excess Mortality Percentage

    by Andy Yuan, Vladimir Atanasov, Paula Natalia Barreto Parra, Jeff Whittle, John Meurer, Benjamin Weston, Qian (Eric) Luo, Lorenzo Franchi, Ruohao Zhang, Bernard Black

    COVID-19 vaccines have saved millions of lives and prevented countless adverse patient disease outcomes. Understanding the long-term effectiveness of these vaccines is imperative to developing recommendations for precautions and booster doses. Comparisons between more and less vaccinated groups may be misleading due to selection bias, as these groups may differ in underlying health status and thus risk of adverse COVID-19 outcomes. We study all adult deaths over April 1, 2021-June 30, 2022 in Milwaukee County, Wisconsin, linked to vaccination records, use mortality from other natural causes to proxy for underlying health, and report relative COVID-19 mortality risk (RMR) for vaccinees versus the unvaccinated, using a novel outcome measure that controls for selection effects. This measure, COVID Excess Mortality Percentage (CEMP) uses the non-COVID natural mortality rate (Non-Covid-NMR) as a measure of population risk of COVID mortality without vaccination. We validate this measure during the pre-vaccine period (r = 0.97) and demonstrate that selection effects are large, with Non-Covid-NMRs for two-dose vaccinees less than half those for the unvaccinated, and Non-COVID NMRs still lower for three dose (booster) recipients. Progressive waning of two-dose effectiveness is observed, with relative mortality risk (RMR) for two-dose vaccinees aged 60 + versus the unvaccinated of 11% during April-June 2021, rising steadily to 36% during the Omicron period (January-June, 2022). Notably, a booster dose reduced RMR to 10–11% for ages 60+. Boosters thus provide important additional protection against mortality.


  • The Trouble with Instruments: The Need for Pretreatment Balance in Shock-Based Instrumental Variable Designs

    by Vladimir Atanasov, Bernard Black

    Credible causal inference in accounting and finance research often comes from natural experiments. These experiments can be exploited using several shock-based research designs, including difference in differences (DID), shock-based instrumental variable (shock-IV), and regression discontinuity. We study here shock-IV designs using panel data. We identify all shock-IV papers in two broad data sets and reexamine three of the apparently strongest papers—Desai and Dharmapala [Desai M, Dharmapala D (2009) Corporate tax avoidance and firm value. Rev. Econom. Statist. 91:537–546.], Duchin et al. [Duchin R, Matsusaka J, Ozbas O (2010) When are outside directors effective? J. Financial Econom. 95:195–214.], and Iliev [Iliev P (2010) The effect of SOX Section 404: Costs, earnings quality, and stock prices. J. Finance 65:1163–1196.]. After we enforce covariate balance and common support for treated and control firms, the instruments in all three papers are unusable—they are no longer significant in the first stage. All three papers also show nonparallel pretreatment trends on outcomes or core covariates. The problems with these papers generalize to our full sample and to other papers exploiting the same shocks as Duchin et al. A core conclusion of our reexamination is that pretreatment balance (common support, covariate balance, and parallel pretreatment trends) is necessary for credible shock-IV designs. We provide a good-practice checklist for shock-IV design with panel data, much of which also applies to DID designs. This paper was accepted by Shiva Rajgopal, accounting.


  • Top Cited Papers

    Shock-Based Causal Inference in Corporate Finance and Accounting Research

    by Vladimir Atanasov, Bernard Black

    Publishers of Foundations and Trends, making research accessible